These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 29280800)

  • 1. The FDA's Latest Response to Opioid Abuse and Overdose.
    Aschenbrenner DS
    Am J Nurs; 2018 Jan; 118(1):22-23. PubMed ID: 29280800
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and performance of current abuse-deterrent formulations.
    Ahmad R; Alaei S; Omidian H
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1255-1271. PubMed ID: 30408424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abuse-deterrent Opioid Formulations.
    Litman RS; Pagán OH; Cicero TJ
    Anesthesiology; 2018 May; 128(5):1015-1026. PubMed ID: 29252508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laboratory-based testing to evaluate abuse-deterrent formulations and satisfy the Food and Drug Administration's recommendation for Category 1 Testing.
    Altomare C; Kinzler ER; Buchhalter AR; Cone EJ; Costantino A
    J Opioid Manag; 2017; 13(6):441-448. PubMed ID: 29308590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abuse-Deterrent Opioid Formulations #329.
    O'Neill R; Lor K; Pruskowski J
    J Palliat Med; 2017 Jun; 20(6):676-678. PubMed ID: 28333577
    [No Abstract]   [Full Text] [Related]  

  • 6. Insights and issues from FDA Advisory Committee meetings on abuse-deterrent opioids.
    Miller CJ; Dart RC; Katz NP; Webster LR
    J Opioid Manag; 2017; 13(6):379-389. PubMed ID: 29308585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interpreting labels of abuse-deterrent opioid analgesics.
    Webster LR
    J Opioid Manag; 2017; 13(6):415-423. PubMed ID: 29308588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the abuse potential of opioids and abuse-deterrent -opioid formulations: A review of clinical study methodology.
    Setnik B; Schoedel KA; Levy-Cooperman N; Shram M; Pixton GC; Roland CL
    J Opioid Manag; 2017; 13(6):485-523. PubMed ID: 29308594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA Boxed Warning for Immediate-Release Opioids.
    Food And Drug Administration Public Health Service U S Department Of Health And Human Services
    J Pain Palliat Care Pharmacother; 2016 Jun; 30(2):141-5. PubMed ID: 27301692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Abuse-related adverse drug reactions and abuse deterrent formulations].
    Papaseit E; Pérez-Mañá C; Torrens M; Farré M
    Med Clin (Barc); 2013 Nov; 141(10):454-8. PubMed ID: 24144061
    [No Abstract]   [Full Text] [Related]  

  • 11. Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations.
    Gasior M; Bond M; Malamut R
    Postgrad Med; 2016 Jan; 128(1):85-96. PubMed ID: 26566680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An overview of prodrug technology and its application for developing abuse-deterrent opioids.
    Gudin JA; Nalamachu SR
    Postgrad Med; 2016 Jan; 128(1):97-105. PubMed ID: 26615852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and impact of prescription opioid abuse deterrent formulation technologies.
    Alexander L; Mannion RO; Weingarten B; Fanelli RJ; Stiles GL
    Drug Alcohol Depend; 2014 May; 138():1-6. PubMed ID: 24613631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abuse-Deterrent Opioid Formulations - Putting the Potential Benefits into Perspective.
    Becker WC; Fiellin DA
    N Engl J Med; 2017 Jun; 376(22):2103-2105. PubMed ID: 28564568
    [No Abstract]   [Full Text] [Related]  

  • 15. Regulatory and evidence-based considerations for abuse-deterrent opioids.
    Loeser KC; Rodriguez R
    Am J Health Syst Pharm; 2019 Jan; 76(2):114-118. PubMed ID: 30689701
    [No Abstract]   [Full Text] [Related]  

  • 16. Protocol: changes in rates of opioid overdose and poisoning events in an integrated health system following the introduction of a formulation of OxyContin® with abuse-deterrent properties.
    Janoff SL; Perrin NA; Coplan PM; Chilcoat HD; Campbell CI; Green CA
    BMC Pharmacol Toxicol; 2016 May; 17(1):21. PubMed ID: 27177423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA opioid safety plan promotes patient, physician education to prevent abuse.
    Kuehn BM
    JAMA; 2010 Aug; 304(8):845. PubMed ID: 20736462
    [No Abstract]   [Full Text] [Related]  

  • 18. Societal economic benefits associated with an extended-release opioid with abuse-deterrent technology in the United States.
    Kirson NY; Shei A; White AG; Birnbaum HG; Ben-Joseph R; Rossiter LF; Michna E
    Pain Med; 2014 Sep; 15(9):1450-4. PubMed ID: 25041231
    [No Abstract]   [Full Text] [Related]  

  • 19. A Proactive Response to Prescription Opioid Abuse.
    Califf RM; Woodcock J; Ostroff S
    N Engl J Med; 2016 Apr; 374(15):1480-5. PubMed ID: 26845291
    [No Abstract]   [Full Text] [Related]  

  • 20. ADF: Abuse-Deterrent Formulation or Another Disillusioned Formulation?
    Brooks A; Kominek C
    Pain Med; 2018 May; 19(5):907-909. PubMed ID: 29025056
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.